Allergy Therapeutics (AGY) — Financial Flexibility Index
Allergy Therapeutics (AGY) has a Financial Flexibility Index of -0.13x as of December 2025. Free cash flow of GBX-8.90 Million (operating CF GBX-11.71 Million minus capex GBX2.81 Million) represents 0% of total liabilities (GBX66.75 Million). Check Allergy Therapeutics (AGY) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Allergy Therapeutics Financial Flexibility Index (2002–2025)
Historical Financial Flexibility Index trend for Allergy Therapeutics across 24 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Allergy Therapeutics.
Annual Financial Flexibility Index for Allergy Therapeutics (2002–2025)
Year-by-year free cash flow to debt coverage for Allergy Therapeutics. Explore Allergy Therapeutics cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.27x | GBX-25.45 Million | GBX-28.72 Million | GBX95.74 Million | ▲ +43.5% |
| 2024 | -0.47x | GBX-28.74 Million | GBX-32.14 Million | GBX61.12 Million | ▼ -15.9% |
| 2023 | -0.41x | GBX-26.25 Million | GBX-30.92 Million | GBX64.70 Million | ▼ -29.1% |
| 2022 | -0.31x | GBX-11.05 Million | GBX-14.11 Million | GBX35.18 Million | ▼ -212.2% |
| 2021 | 0.28x | GBX11.08 Million | GBX8.52 Million | GBX39.55 Million | ▼ -19.8% |
| 2020 | 0.35x | GBX14.82 Million | GBX12.28 Million | GBX42.44 Million | ▲ +28.5% |
| 2019 | 0.27x | GBX8.41 Million | GBX5.60 Million | GBX30.94 Million | ▲ +523.3% |
| 2018 | -0.06x | GBX-1.80 Million | GBX-3.80 Million | GBX27.98 Million | ▼ -204.2% |
| 2017 | 0.06x | GBX1.68 Million | GBX178.00K | GBX27.22 Million | ▲ +115.3% |
| 2016 | -0.40x | GBX-10.61 Million | GBX-11.84 Million | GBX26.36 Million | ▼ -255.0% |
| 2015 | 0.26x | GBX4.21 Million | GBX3.12 Million | GBX16.23 Million | ▲ +12.6% |
| 2014 | 0.23x | GBX3.07 Million | GBX2.17 Million | GBX13.32 Million | ▲ +1.3% |
| 2013 | 0.23x | GBX3.25 Million | GBX2.43 Million | GBX14.29 Million | ▼ -27.7% |
| 2012 | 0.31x | GBX4.14 Million | GBX2.88 Million | GBX13.16 Million | ▲ +1234.3% |
| 2011 | -0.03x | GBX-790.00K | GBX-2.03 Million | GBX28.48 Million | ▼ -120.6% |
| 2010 | 0.13x | GBX3.40 Million | GBX1.70 Million | GBX25.23 Million | ▲ +376.1% |
| 2009 | 0.03x | GBX1.28 Million | GBX-440.00K | GBX45.25 Million | ▲ +105.8% |
| 2008 | -0.48x | GBX-16.70 Million | GBX-19.32 Million | GBX34.47 Million | ▲ +52.7% |
| 2007 | -1.02x | GBX-15.77 Million | GBX-18.88 Million | GBX15.40 Million | ▲ +10.3% |
| 2006 | -1.14x | GBX-5.91 Million | GBX-8.10 Million | GBX5.18 Million | ▼ -987.3% |
| 2005 | 0.13x | GBX846.00K | GBX-57.00K | GBX6.58 Million | ▼ -79.9% |
| 2004 | 0.64x | GBX2.67 Million | GBX1.91 Million | GBX4.16 Million | ▲ +43.6% |
| 2003 | 0.45x | GBX2.50 Million | GBX2.10 Million | GBX5.60 Million | ▲ +474.0% |
| 2002 | -0.12x | GBX-1.68 Million | GBX-2.01 Million | GBX14.07 Million | — |